Restoring Parkin Function: An AAV Gene Therapy Approach for Early-Onset Parkinson's Disease
Sambuddha BasuiD, Tyler G. Demarest, Nicholas J. Gattone, Alexandra J Gilsrud, Brittany Wicks, Apeksha Khatiwada, Mohammad Nayal, Renee C. Gentzel, Daniel Cohen, Eric Wildon KostukiD, Derek P. NarendraiD, Pedro Gonzalez‐AlegreiD, Maria Grazia BiferiiD, Elizabeth A. Ramsburg
Abstract
BackgroundBiallelic loss-of-function mutations in PRKN gene (encoding Parkin protein) cause early-onset Parkinsons disease (EOPD). Parkin is a crucial component of PINK1-Parkin pathway, which marks damaged mitochondria for degradation via mitophagy. Without functional Parkin, damaged mitochondria accumulate, causing oxidative stress and neurodegeneration. ObjectiveInvestigate Parkin gene replacement via AAV gene therapy as a potential treatment for Parkin-dependent EOPD. MethodsWe initially validated phosphorylated ubiquitin Ser65 (pUbSer65) as an indicator of Parkin-mediated mitophagy initiation. We evaluated AAV-mediated PRKN replacement (hereafter, AAV-Parkin) in a Parkin knockout neuroblastoma cell line (SH-SY5Y cells) and feasibility of delivery in mouse and rat models. ResultsOur research showed pUbSer65 signal was reduced in Parkin-KO SH-SY5Y cells when compared to wild-type cells after mitochondrial stress, indicating deficiency in initiation of mitophagy. AAV-mediated human PRKN gene replacement successfully restored these pUbSer65 levels in knockout cells. We saw restoration in patient-derived fibroblasts following AAV-Parkin overexpression. We developed a translatable gene therapy approach using rodents. We demonstrated the feasibility of delivering AAV-Parkin directly into the substantia nigra (SN) of wild-type rats. Using an AAV1 capsid with Ef1a promoter, we achieved dose-dependent Parkin expression and identified a well-tolerated dose. We also evaluated multiple promoters in a proprietary Spark100 capsid, finding Ef1a and Synapsin1 (Syn1) were most effective for transducing dopaminergic neurons in the SN of mice without causing adverse effects. These findings established a well-tolerated vector dose and an optimal capsid-promoter combination. ConclusionsOur results support the potential of AAV-Parkin gene therapy as a disease-modifying approach for Parkin-deficient EOPD. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=132 SRC="FIGDIR/small/737487v1_ufig1.gif" ALT="Figure 1"> View larger version (33K): org.highwire.dtl.DTLVardef@16dd13corg.highwire.dtl.DTLVardef@c3dfcdorg.highwire.dtl.DTLVardef@19a310dorg.highwire.dtl.DTLVardef@a66f2_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Parkin deficiency rewires the genetic dependencies that govern neuronal survival
Shijie Wang, Daniel R. Gulbranson, … Steven M. Finkbeiner·bioRxiv·Oct 28, 2026
- CRISPR/Cas9-mediated gene editing induces neurological recovery in an A53T-SNCA overexpression rat model of Parkinson's disease
Hyung Ho Yoon, Sunghyeok Ye, … Sang Ryong Jeon·The CRISPR JournalPeer-reviewed·Feb 1, 2022
- A Versatile AAV-TH-SNCA Model to Study Early α-Synuclein Pathology and Intervention
Sabina Marciano, Leandra G. Velazquez, … Roberta Marongiu·bioRxiv·Apr 30, 2026
- Oxidative switch drives mitophagy defects in dopaminergic parkin mutant patient neurons
Aurélie Schwartzentruber, Camilla Boschian, … Heather Mortiboys·Scientific ReportsPeer-reviewed·Sep 23, 2020
- Age-related decline of PKA-RIIβ level in SNc dopaminergic neurons underlies PD pathogenesis
Yun Zhao, Bingwei Wang, … Ruimao Zheng·bioRxiv·Sep 13, 2024
- Co-editing PINK1 and DJ-1 genes via AAV-delivered CRISPR/Cas9 system in adult monkey brains elicits classic Parkinsonian phenotypes
Hao Li, Shihao Wu, … Xintian Hu·Neuroscience BulletinPeer-reviewed·Jun 24, 2021